Mathieu Rouanne

7PUBLICATIONS
112CO-AUTHORS
BiomaterialsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosisPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 22, 2026
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.

|Nov 18, 2024
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy.

Mathieu Rouanne, Noah Chen, Dylan L Mariuzza

|Oct 18, 2024
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.

Fangda Li, Zaofeng Yang, Thomas M Savage

|Oct 12, 2023
Probiotic-guided CAR-T cells for solid tumor targeting.

Rosa L Vincent, Candice R Gurbatri, Fangda Li

|Jan 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.

François-Xavier Danlos, Matthieu Texier, Bastien Job

|Aug 05, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.

Anne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva

Pageof 2

Frequent Collaborators

4 joint publications

Nicholas Arpaia

3 joint publications

Kenia de Los Santos-Alexis

3 joint publications

Rosa L Vincent

3 joint publications

Tal Danino